beremagene geperpavec
AXP000193.2 · Viral vector gene therapy
- Platform
- HSV-1 (replication-defective)
- Targets
- COL7A1
- Originator
- Krystal Biotech
- Sponsor
- Krystal Biotech
Names
| Name | Type | Source |
|---|---|---|
| beremagene geperpavec | preferred name, INN | curator, ncit |
| Vyjuvek | brand | fda |
| B-VEC | code | ncit |
| KB103 | code | ncit |
| beremagene geperpavec-svdt | synonym | ncit |
Virus
- Role
- In vivo gene transfer
- Family
- Herpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Replication
- non replicating
- Modifications
- replication-defective HSV-1 backbone (specific deletions not verified here); two copies of COL7A1 inserted
- Transgenes
- COL7A1
- Route
- topical
- Source
- evidence
Cross-references
- NCI Thesaurus
- C174623
- Wikidata
- Q119475442
- FDA UNII
- AQN7K24KQU
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| FDA | US | 2023-05-19 | approved | Vyjuvek | Treatment of wounds in adult and paediatric patients with dystrophic epidermolysis bullosa with mutation(s) in the COL7A1 gene | source |
| EMA | EU | 2025-04-23 | approved | Vyjuvek | Treatment of wounds in patients from birth with dystrophic epidermolysis bullosa with mutation(s) in the COL7A1 gene | source |
| PMDA | JP | 2025-07-24 | approved | Vyjuvek | Dystrophic epidermolysis bullosa | source |
Clinical trials (4)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06731933 | Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin | Recruiting | Phase 2 | 2025-03-28 | 2027-02 | 16 | Squamous Cell Carcinoma |
| NCT04917874 | A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa | Completed | Phase 3 | 2021-05-25 | 2023-07-31 | 47 | DEB - Dystrophic Epidermolysis Bullosa; Dominant Dystrophic Epidermolysis Bullosa; Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa |
| NCT04491604 | Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB | Completed | Phase 3 | 2020-08-17 | 2021-10-29 | 31 | Dominant Dystrophic Epidermolysis Bullosa; Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa |
| NCT03536143 | A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients | Completed | Phase 1/2 | 2018-05-06 | 2019-11-01 | 12 | Dystrophic Epidermolysis Bullosa |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41025539 | Off-Label Use of Double-Dose Beremagene Geperpavec (B-VEC) in the Treatment of Recessive Dystrophic Epidermolysis Bullosa: A Promising Clinical Case. | Pediatric dermatology | 2026 | name in title: beremagene geperpavec |
| PMID 40220208 | Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa. | American journal of clinical dermatology | 2025 | cited by trial NCT04917874 |
| PMID 40667654 | Efficacy and Safety of the Topical Gene Therapy Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Study of Japanese Subjects With Dystrophic Epidermolysis Bullosa. | The Journal of dermatology | 2025 | name in title: beremagene geperpavec-svdt |
| PMID 41523446 | Scarring Alopecia in Localized Dystrophic Epidermolysis Bullosa: A Case Report and a Scoping Review. | Cureus | 2025 | name in abstract: beremagene geperpavec |
| PMID 38324486 | Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa. | The New England journal of medicine | 2024 | name in abstract: beremagene geperpavec |
| PMID 35347281 | In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. | Nature medicine | 2022 | cited by trial NCT03536143 |
| PMID 36516090 | Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. | The New England journal of medicine | 2022 | cited by trial NCT04491604 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40158551 | VYJUVEK for dystrophic epidermolysis bullosa: Ethical dilemmas in access and pricing. | Journal of the American Academy of Dermatology | 2026 | name in title: Vyjuvek |
| PMID 40892156 | Beremagene geperpavec (B-VEC) for infantile dystrophic epidermolysis bullosa: Benefit of early intervention. | Journal of the European Academy of Dermatology and Venereology : JEADV | 2026 | name in title: beremagene geperpavec |
| PMID 41731282 | Developing CRISPR-Based Therapies for Epidermolysis Bullosa: A Comprehensive Review of Current Strategies. | Drugs | 2026 | name in abstract: beremagene geperpavec |
| PMID 41772988 | Understanding the efficacy and tolerability of topical therapies for epidermolysis bullosa. | Expert review of clinical pharmacology | 2026 | name in abstract: beremagene geperpavec |
| PMID 42578000 | Topical gene therapy for severe recessive dystrophic epidermolysis bullosa: clinical outcomes and multidisciplinary management in three patients treated with beremagene geperpavec (B-VEC) in Italy - a case series. | Drugs in context | 2026 | name in title: beremagene geperpavec |
| PMID 42696401 | Update on Approved Therapies for Dystrophic and Junctional Epidermolysis Bullosa. | Pediatric dermatology | 2026 | name in abstract: beremagene geperpavec-svdt |
| PMID 43018251 | Real-world effects of beremagene geperpavec in epidermolysis bullosa. | Journal of the European Academy of Dermatology and Venereology : JEADV | 2026 | name in title: beremagene geperpavec |
| PMID 40464880 | Correction to: Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa. | American journal of clinical dermatology | 2025 | name in title: beremagene geperpavec-svdt |
| PMID 40564391 | Towards Extracellular Vesicles in the Treatment of Epidermolysis Bullosa. | Bioengineering (Basel, Switzerland) | 2025 | name in abstract: Vyjuvek |
| PMID 41210910 | The Saudi National Policy and Protocol for Epidermolysis Bullosa. | Risk management and healthcare policy | 2025 | name in abstract: beremagene geperpavec |
| PMID 37936299 | Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critically appraised research paper. | The British journal of dermatology | 2024 | name in title: beremagene geperpavec |
| PMID 38294784 | Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa. | JAMA dermatology | 2024 | name in title: beremagene geperpavec |
| PMID 38396920 | Emerging Gene Therapeutics for Epidermolysis Bullosa under Development. | International journal of molecular sciences | 2024 | name in abstract: beremagene geperpavec |
| PMID 38724041 | Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa. | The Journal of dermatological treatment | 2024 | name in title: beremagene geperpavec-svdt |
| PMID 39292470 | Estimating Costs in Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa. | JAMA dermatology | 2024 | name in title: beremagene geperpavec |
| PMID 39292476 | Estimating Costs in Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa-Reply. | JAMA dermatology | 2024 | name in title: beremagene geperpavec |
| PMID 37432558 | Beremagene Geperpavec: First Approval. | Drugs | 2023 | name in title: beremagene geperpavec |
| PMID 37595560 | Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB). | Cell | 2023 | name in abstract: beremagene geperpavec |
| PMID 38004669 | Attenuated Replication-Competent Herpes Simplex Virus Expressing an ECM-Modifying Transgene Hyaluronan Synthase 2 of Naked Mole Rat in Oncolytic Gene Therapy. | Microorganisms | 2023 | name in abstract: beremagene geperpavec |
| PMID 38098548 | Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa. | Annals of medicine and surgery (2012) | 2023 | name in title: Vyjuvek |
Unconfirmed matches (4)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42648642 | Engineering HSV-1 for gene therapy, oncolytic immunotherapy, and neuroscience. | Virologica Sinica | 2026 | name in abstract: B-VEC |
| PMID 38085193 | Current Treatment Landscape for Dystrophic Epidermolysis Bullosa: From Surgical Management to Emerging Gene Therapies and Novel Skin Grafts. | The Journal of hand surgery | 2024 | name in abstract: B-VEC |
| PMID 38275540 | Management of Skin Lesions in Patients with Epidermolysis Bullosa by Topical Treatment: Systematic Review and Meta-Analysis. | Healthcare (Basel, Switzerland) | 2024 | name in abstract: B-VEC |
| PMID 8088537 | A genetic and molecular characterization of the recA gene from Staphylococcus aureus. | Gene | 1994 | name in abstract: KB103 |
Notes
Vyjuvek: topical gel of a replication-defective HSV-1 vector carrying two copies of COL7A1, for wounds of dystrophic epidermolysis bullosa. FDA approved 19 May 2023 (first redosable topical gene therapy), European Commission 23 April 2025, Japan (MHLW) September 2025. An eye-drop formulation for ocular DEB complications is the same product in a different formulation, so not a separate program.
How to cite
beremagene geperpavec (AXP000193.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000193.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.